DePuy Synthes Partners with CGBIO for NOVOSIS Distribution
DePuy Synthes has entered into an exclusive distribution agreement with CGBIO for the commercialization of NOVOSIS, an advanced bone graft substitute containing growth factors, across its orthopaedic portfolio, including spine, craniomaxillofacial (CMF), and trauma.
RAYNHAM, Mass.–(BUSINESS WIRE)–DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced an exclusive distribution agreement1 with CGBIO, a biotechnology company specializing in regenerative medicine, for the development and commercialization of NOVOSIS, an advanced bone graft substitute containing growth factors, across its orthopaedic portfolio including spine, craniomaxillofacial (CMF), and trauma. NOVOSIS is a novel growth-factor bone graft substitute desig
